Special Issue

Infection and Treatment of Antibiotic-Resistant ESKAPE Pathogens

Message from the Guest Editors

The global challenge posed by bacterial infections, often accompanied by intricate antibiotic resistance patterns, significantly impacts human health. Antibiotics, while effective, wield a double-edged sword: they eliminate germs but simultaneously exert selective pressure on bacteria to evolve resistance. Furthermore, antibiotic use disrupts the gut microbiota, fostering a reservoir of antimicrobial resistance genes and organisms, along with complications like antibiotic-associated diarrhea and superinfections. In contrast, pathogen-specific alternatives offer distinct advantages over antibiotics. This Special Issue aims to compile novel research on alternative therapies combating bacterial infections. We seek studies on novel antimicrobials and innovative antibiotic alternatives. The precise characterizations of antimicrobial agents effective against multidrugresistant infections are of particular interest. Additionally, we invite contributions in the form of review articles or concise reflections on these critical topics. We eagerly await your submissions. Dr. Peng Gao Dr. Jie Shen

Guest Editors

Dr. Peng Gao

Applied Oral Sciences & Community Dental Care, Faculty of Dentistry, The University of Hong Kong, Hong Kong, China

Dr. Jie Shen

Department of Spine Surgery, Peking University Shenzhen Hospital, Peking University, Beijing, China

Deadline for manuscript submissions

closed (20 March 2025)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/199663

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

